Corinne Jenkins
Stock Analyst at Goldman Sachs
(1.66)
# 3,382
Out of 4,996 analysts
58
Total ratings
43.9%
Success rate
-4.49%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Corinne Jenkins
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $105 → $138 | $99.16 | +39.17% | 9 | Sep 24, 2025 | |
| ROIV Roivant Sciences | Maintains: Buy | $20 → $24 | $15.17 | +58.21% | 6 | Sep 18, 2025 | |
| GERN Geron | Reinstates: Sell | $1 | $1.29 | -22.48% | 4 | Jul 10, 2025 | |
| TGTX TG Therapeutics | Maintains: Neutral | $20 → $22 | $35.50 | -38.03% | 8 | Nov 5, 2024 | |
| FULC Fulcrum Therapeutics | Upgrades: Buy | $6 → $15 | $8.84 | +69.68% | 2 | May 14, 2024 | |
| IDYA IDEAYA Biosciences | Maintains: Buy | $53 → $46 | $26.83 | +71.45% | 5 | May 13, 2024 | |
| ALT Altimmune | Reinstates: Neutral | $13 | $4.00 | +225.00% | 3 | Jan 24, 2024 | |
| HRMY Harmony Biosciences Holdings | Maintains: Sell | $25 → $28 | $27.51 | +1.78% | 7 | Jan 9, 2024 | |
| BTAI BioXcel Therapeutics | Maintains: Neutral | $192 → $64 | $2.70 | +2,270.37% | 6 | Aug 15, 2023 | |
| RAPT RAPT Therapeutics | Maintains: Buy | $216 → $184 | $26.38 | +597.50% | 2 | Mar 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $21 | $1.99 | +955.28% | 2 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $14 | $7.64 | +83.25% | 2 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $160 | $3.86 | +4,045.08% | 2 | Dec 15, 2021 |
Rhythm Pharmaceuticals
Sep 24, 2025
Maintains: Buy
Price Target: $105 → $138
Current: $99.16
Upside: +39.17%
Roivant Sciences
Sep 18, 2025
Maintains: Buy
Price Target: $20 → $24
Current: $15.17
Upside: +58.21%
Geron
Jul 10, 2025
Reinstates: Sell
Price Target: $1
Current: $1.29
Upside: -22.48%
TG Therapeutics
Nov 5, 2024
Maintains: Neutral
Price Target: $20 → $22
Current: $35.50
Upside: -38.03%
Fulcrum Therapeutics
May 14, 2024
Upgrades: Buy
Price Target: $6 → $15
Current: $8.84
Upside: +69.68%
IDEAYA Biosciences
May 13, 2024
Maintains: Buy
Price Target: $53 → $46
Current: $26.83
Upside: +71.45%
Altimmune
Jan 24, 2024
Reinstates: Neutral
Price Target: $13
Current: $4.00
Upside: +225.00%
Harmony Biosciences Holdings
Jan 9, 2024
Maintains: Sell
Price Target: $25 → $28
Current: $27.51
Upside: +1.78%
BioXcel Therapeutics
Aug 15, 2023
Maintains: Neutral
Price Target: $192 → $64
Current: $2.70
Upside: +2,270.37%
RAPT Therapeutics
Mar 15, 2023
Maintains: Buy
Price Target: $216 → $184
Current: $26.38
Upside: +597.50%
Mar 7, 2023
Maintains: Buy
Price Target: $25 → $21
Current: $1.99
Upside: +955.28%
Dec 20, 2022
Maintains: Buy
Price Target: $9 → $14
Current: $7.64
Upside: +83.25%
Dec 15, 2021
Initiates: Neutral
Price Target: $160
Current: $3.86
Upside: +4,045.08%